Aspirin - Angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: A dose-related adverse effect of aspirin

Archives of Internal Medicine

Volumn 163, Issue 13, 2003, Pages 1574-1579

  Guazzi, Marco ^a   Brambilla, Roberto ^a   Rèina, Giuseppe ^a   Tumminello, Gabriele ^a   Guazzi, Maurizio D ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; NITRATE;

ADULT; AGED; ARTICLE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG FATALITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; ITALY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0038494006     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.13.1574     Document Type: Article

References (32)

1. Cleland JGF, Bulpitt CJ, Falk RH, et al. Is aspirin safe for patients with heart failure? Br Heart J. 1995;74:215-219.
2. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ Jr. Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med. 1988;319:761-767.
3. Stys T, Lawson WE, Smaldone GC, et al. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Intern Med. 2000;160:1409-1413.
4. Teerlink JR, Massie BM. The interaction of ACE inhibitors and aspirin in heart failure: torn between two lovers. Am Heart J. 1999;138:193-197.
5. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the cooperative New Scandinavian Enalapril Survival Study II. Am J Cardiol. 1997;79:115-119.
6. Peterson JG, Lauer MS, Young JB, et al. Evidence for an adverse interaction between ACE inhibitors and aspirin following myocardial infarction: the GUSTO-1 trial [abstract]. J Am Coll Cardiol. 1998;31(suppl A):96A.
7. Peterson J, Lauer MS, Lincoff AM, et al. Evidence for a potential adverse interaction between aspirin and angiotensin converting enzyme inhibitors after percutaneous coronary angioplasty: the EPILOG trial [abstract]. J Am Coll Cardiol. 1999;33(suppl A):397A.
8. Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31:419-425.
9. Oosterga M, Anthonio RL, de Kam PJ, Crijne HJ, van Gilst WH. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol. 1998;81:1178-1181.
10. Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999;33:1920-1925.
11. Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. J Am Coll Cardiol. 2000;35:1801-1807.
12. Krumholz HM, Chen TC, Wang Y, et al. Aspirin and angiotensin-converting-enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction. Arch Intern Med. 2001;161:538-544.
13. Tohgi H, Konno S, Tamura K, et al. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke. 1992;23:1400-1403.
14. Guazzi MD, Campodonico J, Celeste F, et al. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin Pharmacol Ther. 1998;63:79-86.
15. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intense blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351: 1755-1762.
16. Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. Circulation. 1998;98:757-765.
17. Davie AP, Love MP, McMurray JJV. Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. Clin Pharmacol Ther. 2000;67:530-537.
18. Hall D. The aspirin - angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not. J Am Coll Cardiol. 2000;35:1808-1812.
19. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308:81-106.
20. Nawarskas JJ, Spinler SA. Update of the interaction between aspirin and angiotensin-converting enzyme inhibitors. Pharmacotherapy. 2000;20:698-710.
21. Krumholz HM, Chen YT, Radford MJ, Aspirin in the treatment of heart failure in the elderly. Arch Intern Med. 2001;161:577-582.
22. Jhund PS, Davie AP, McMuray JJV. Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:1234-1238.
23. Packer M, Cohn JN, for the Steering Committee and Membership of the Advisory Council to Improve Outcome Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999; 82:2A-38A.
24. Linz W, Wiemer G, Gohlke P, et al. Contributions of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47: 25-49.
25. Guazzi M, Marenzi G, Alimento M, et al. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation. 1997;95:1930-1936.
26. Guazzi M, Agostoni P, Guazzi MD. Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure. J Am Coll Cardiol. 2001;37:398-406.
27. Guazzi M, Pontone G, Agostoni P. Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. Am Heart J. 1999;138:254-260.
28. Parameshwar J, Keegan J, Sparrow J, et al. Predictors of prognosis in severe chronic heart failure. Am Heart J. 1992;123:421-426.
29. Chua TP, Ponikowski P, Harrington D, et al. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol. 1997;29:1585-1590.
30. Guazzi M, Pontone G, Brambilla R, Agostoni P, Reina G. Alveolar - capillary membrane gas conductance: a novel prognostic indicator in chronic heart failure. Eur Heart J. 2002;23:467-476.
31. Baur LH, Schipperheyn JJ, van der Laarse A, et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J. 1995; 73:227-236.
32. Massie BM, Armstrong PW, Cleland JGF, et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. Arch Intern Med. 2001;161:165-171.